Immutep vs Zentalis Pharmaceuticals
IMMP and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMMP and ZNTL compare
Immutep scores higher on the StockData Score (8 against 6 for Zentalis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMMP | ZNTL |
|---|---|---|
| Size and price | ||
| Market cap | – | $122M |
| Share price | $3.48 | $1.70 |
| Change, 1 year | −90.3% | 26.9% |
| Change, 5 years | −95.4% | −97.8% |
| Beta (5Y) | 1.67 | 2.14 |
| Employees | 46 | 106 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.6× |
| FCF yield | – | −110% |
| Growth | ||
| Revenue growth (TTM) | 134% | – |
| Revenue growth, 5Y average | 43.5% | – |
| Profitability | ||
| Net margin | −328% | – |
| FCF margin | −230% | – |
| Return on equity | −77.3% | −61.9% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.69 | 7.33 (better) |
| Altman Z-score | – | −6.54 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 66.1% |
| Held by insiders | 0.89% | 58.0% |
| Insider net buying, 12 months | – | $12.8M |
| Short interest, % of float | – | 16.7% |
Go deeper
- IMMP stock overview
- IMMP income statement
- IMMP valuation and score
- ZNTL stock overview
- ZNTL income statement
- ZNTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.